CI

At a glance

ClinicalIndex Comparison Record
Phase 2Unknown· 240 target
Drug / intervention
The KPCXM18 injection +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05745311
NCT05745311Phase 2Unknown
CompareCT.gov

A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase II Clinical Trial Evaluating the Efficacy and Safety of the KPCXM18 Injection in Patients With Acute Ischemic Stroke.

Kunming Pharmaceuticals, Inc.·interventional·Posted Feb 27, 2023·Updated Feb 28, 2023

In Brief

A Phase 2 clinical trial evaluating The KPCXM18 injection and Placebo for Acute Ischemic Stroke. Targeting 240 participants.

Detailed Summary

This study is a multicenter, randomized, double-blind, parallel, placebo-controlled trial design to evaluate the efficacy and safety of the KPCXM18 injection at different doses for the treatment of acute ischemic stroke and its PK/PD characteristics in patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Ischemic Stroke
Countries--
Collaborators--

Timeline

Phase 2UnknownOverdue
202420252026
First PostedFeb 27, 2023
Enrollment StartMar 1, 2023
Primary CompletionMay 1, 2024
Study CompletionJul 30, 2024
TodayJul 1, 2026
Enrollment to primary: 1.2 yearsPosted 3.3 years ago

Interventions

The KPCXM18 injectiondrug

Intravenous infusion

Placebodrug

Intravenous infusion